Program
NTQ5082
A development code. Also written as “NTQ5082 capsules 200 mg”, “NTQ5082 100mg qd” and “NTQ5082 200mg qd”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA, led by Sino Biopharmaceutical.
Furthest: phase 3, since Sep 10, 20256 company-led studies, 6 open or runningNext primary completion: Nov 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 66 open or running | phase 3since Sep 10, 2025 | Jul 23, 2024 | Nov 2026phase 3 · NCT07177859 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2024First studies: 2 phase 1 studies in Complement-mediated Hemolytic DiseasesFirst studyNCT06560593, NCT06558656
- Dec 24, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06764303 · 24 enrolled · China
- May 12, 2025Phase 2 study in Glomerulonephritis, IGANCT06982040 · 80 planned
- Sep 10, 20252 phase 3 studies in Hemoglobinuria, ParoxysmalNCT07177872, NCT07177859
Ahead
- Nov 2026Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07177859
- Jun 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07177872
TargetBeta
CFB →read by rule
“NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.”study text, by rule · the study
Other programs on CFB
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07177872Hemoglobinuria, Paroxysmal · China | 3 | Not yet recruiting | Jun 2028 | 78 |
| NCT07177859Hemoglobinuria, Paroxysmal · China | 3 | Not yet recruiting | Nov 2026 | 78 |
| NCT06982040Glomerulonephritis, IGA | 2 | Not yet recruiting | Sep 2026 | 80 |
| NCT06764303Hemoglobinuria, Paroxysmal · China | 2 | Active, not recruiting | Jul 8, 2025 | 24 |
| NCT06560593Complement-mediated Hemolytic Diseases · China | 1 | Not yet recruiting | Dec 2024 | 82 |
| NCT06558656Complement-mediated Hemolytic Diseases · China | 1 | Not yet recruiting | Dec 2024 | 12 |
How it is read
Names in the registry
- “NTQ5082 capsules 200 mg”, 3 entries
- “NTQ5082 100mg qd”, 1 entry
- “NTQ5082 200mg qd”, 1 entry
- “NTQ5082 capsules 100 mg”, 1 entry
- “NTQ5082 capsules 300 mg”, 1 entry
Codes read as this program: NTQ5082.
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 3 studies
- Glomerulonephritis, IGA, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.